Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA.
Adv Drug Deliv Rev. 2021 May;172:314-338. doi: 10.1016/j.addr.2021.01.014. Epub 2021 Jan 20.
The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.
持续的 SARS-CoV-2 大流行促使人们集中资源和专业知识，致力于开发研究性疫苗以预防 COVID-19。私营企业、政府和非政府组织之间的高度协作的全球努力，使得一些 SARS-CoV-2 疫苗候选物在大流行开始仅数月后就进入了 III 期临床试验。在这篇综述中，我们概述了目前处于 III 期临床试验阶段和少数已授权紧急使用的 SARS-CoV-2 疫苗的临床前和临床数据。我们还进一步讨论了相关的疫苗平台，并讨论了可能被靶向以增加疫苗反应的广度和持久性的 SARS-CoV-2 抗原。
